38 results about "Local injection" patented technology

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.

The invention discloses an engineered macrophage and a pharmaceutical composition and application thereof, and CCM3 expression in the engineered macrophage is inhibited, so that the engineered macrophage is polarized towards the M2 direction or the engineered macrophage is an M2 type macrophage. Besides, the invention further develops a temperature-sensitive cell-loaded hydrogel preparation which can promote polarization of macrophages in the M2 direction by inhibiting expression of signal molecules CCM3 on adhesion spots, and the temperature-sensitive cell-loaded hydrogel preparation can promote bone defect immune osteogenesis through local injection.

This invention relates to a locally injectable hydrogel for treating pancreatic cancer, its preparation method, and its application. The hydrogel is prepared from raw materials comprising hyaluronic acid-dopamine and a radionuclide. Through extensive research and optimization, this invention has discovered that reacting hyaluronic acid-dopamine and a radionuclide in a suitable temperature and solvent, followed by mixing the resulting reaction solution with an alkaline sodium periodate solution and rapid stirring, successfully prepares a locally injectable hydrogel highly suitable for treating pancreatic cancer. The hydrogel is prepared under mild conditions, has a simple composition, and high safety. It effectively addresses the core bottlenecks in local radiotherapy for pancreatic cancer, such as poor stability of radionuclide carriers, short retention time, and uncontrollable release. Furthermore, it can reshape the body's immune microenvironment and enhance anti-tumor immune responses, significantly improving therapeutic efficacy. This has significant clinical implications for overcoming the current limitations in the treatment of locally advanced unresectable pancreatic cancer.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention provides a hydrogel sustained-release material loaded with melatonin and mecobalamin as well as a preparation method and application of the hydrogel sustained-release material, and belongs to the technical field of medicine synthesis. According to the invention, HyStem-HP and thiolated gelatin are taken as hydrogel carriers, melatonin and mecobalamin are loaded, and the hydrogel sustained-release material loaded with melatonin and mecobalamin is prepared. A three-dimensional network structure is constructed through a physical or chemical cross-linking technology, synergistic slow release of melatonin and mecobalamin is achieved, the drug action time is prolonged, frequent drug administration requirements are reduced, oxidation resistance and apoptosis resistance of melatonin are combined with the nerve repairing function of mecobalamin, photoreceptor cell degeneration is doubly delayed, and the melatonin-mecobalamin-melatonin-mecobalamin-melatonin-mecobalamin-melatonin-mecobalamin-melatonin-mecobalamin- meanwhile, high-concentration accumulation of the medicine at the retinopathy part can be realized through local injection of the hydrogel, and the medicine is continuously released for several weeks, so that the blood retina barrier limitation is broken through.

To provide a treatment tool for an endoscope capable of suitably performing incision / peeling treatment and local injection treatment and easy to handle.SOLUTION: A treatment tool for an endoscope includes a sheath, an electrode provided at a distal end portion of the sheath so as to be movable forward and backward, a rod provided so as to be movable forward and backward with respect to the electrode and the sheath, a through-hole that extends in a direction along a longitudinal axis of the electrode and through which the rod passes, and a conduit that extends in the direction along the longitudinal axis of the electrode, is a part of a flow path through which a fluid passes, and is different from the through-hole.SELECTED DRAWING: Figure 3

The invention relates to the technical field of biological medicines, and discloses application of a ZBP1 inhibitor in preparation of a medicine for treating cognitive impairment caused by plastics. Research finds that exposure of a specific dose of nano plastic can activate a ZBP1 signal channel in an organism and promote assembly of a pan-apoptosis small body compound, so that pan-apoptosis cascade reaction with pyroptosis, apoptosis and necrosis characteristics is triggered, and finally hippocampal neuron damage, dysfunction and learning and memory ability decline are caused. Further research shows that expression of key protein of pan-apoptosis can be remarkably inhibited through local injection of the ZBP1 inhibitor to the hippocampus, cognitive function impairment induced by nano-plastics is effectively improved, and the key effect of ZBP1 serving as a core factor in the regulation and control process is defined. Based on the discovery, the ZBP1 inhibitor can be used for preparing the medicine for treating the plastic pollution related cognitive impairment, and a brand new treatment strategy is provided for clinical intervention of the diseases.

The invention relates to a treatment tool for an endoscope. The purpose of the present invention is to satisfactorily perform local injection while maintaining tissue incision and dissection properties. This treatment tool for an endoscope is provided with: a sheath (9) having a first hole (921) open at the tip; an electrode (11) that passes through the first hole (921) and has a second hole (113) that opens at the tip; and a needle member (13) that is inserted through the second hole (113), the needle member (13) being capable of protruding from the tip of the second hole (113), and a fluid being injected into the tissue from a gap between the electrode (11) and the needle member (13).

The application discloses application of serine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating intervertebral disc degeneration, and a medicine composition containing the active ingredient, and belongs to the technical field of biological medicine. The application takes serine as the active ingredient, provides application of the serine in preparation of the medicine for treating intervertebral disc degeneration, the medicine can supplement serine exogenously, corrects redox imbalance of nucleus pulposus cells, reverses cell aging, and thus can improve the intervertebral disc degeneration process. The application further provides a corresponding medicine composition, which can be prepared into a local injection preparation or an oral preparation, wherein the local injection preparation can be combined with a biomaterial to construct a slow-release delivery system, so that long-acting targeted drug delivery is achieved.

An injectable bifunctional hydrogel has antibacterial activity. The bifunctional hydrogel is a hydrogel prepared by dissolving nucleoside analogues in a solvent. The nucleoside analog has a structure of formula I. It can be a candidate drug for the local injection treatment of periodontal disease, and it also has potential application prospects in the minimally invasive treatment of craniofacial bone tissue defects.

This invention relates to an endoscopic treatment device. It allows for efficient local injection while maintaining the tissue's ability to cut and dissect. The endoscopic treatment device comprises: a sheath (9) having a first hole (921) opening at its front end; an electrode (11) passing through the first hole (921) and having a second hole (113) opening at its front end; and a needle member (13) passing through the second hole (113), the needle member (13) being able to protrude from the front end of the second hole (113) to inject fluid into the tissue through the gap between the electrode (11) and the needle member (13).

The invention discloses a hollow balloon embedded medicine local injection system, and relates to the technical field of medical instruments. The device comprises an expandable balloon, a hollow catheter, a medicine storage unit and an injection control unit. A pre-buried medicine layer is arranged on the outer surface of the balloon, the hollow catheter directionally impacts the inner wall of the balloon through the fluid jet holes to rapidly dissolve the medicine layer, the medicine storage unit maintains the temperature and pressure of a medicine solution to be stable, and the injection control unit achieves intermittent high-pressure jet output. According to the system, the injection hole design, the porous structure layer and the double-cavity catheter structure are optimized, the drug release efficiency and adaptability are improved, the problems that in the prior art, drug release is uncontrollable, and the system flexibility is insufficient are solved, and the system is suitable for the scenes of vascular interventional therapy, tumor ablation and the like.

The application discloses a YWHAH active polypeptide and a preparation method and application thereof, and belongs to the field of biological medicine and tissue engineering. The polypeptide sequence is LRDNLTLWTSDQQDE or TLWTSDQQDEEAGEG, which can target and block the GREM1 / YWHAH protein complex, and release the inhibition of GERM1 on the BMP signal pathway. Experiments prove that the polypeptide can significantly improve the osteogenic and dentinogenic differentiation ability of dental pulp mesenchymal stem cells, up-regulate the alkaline phosphatase activity and cell mineralization level, promote the expression of osteogenic and dentinogenic marker genes, and induce the formation of bone-like and dentin-like new tissues in vivo. The polypeptide has the advantages of small molecular weight, convenient chemical synthesis, good physicochemical stability, weak immunogenicity and the like, and can be used in stem cell culture preparations, composite tissue engineering scaffolds, local injection drugs and various dosage forms, and has a wide application prospect in various hard tissue defect repair scenes.

The present invention relates to a controlled-release pharmaceutical composition comprising at least a controlled-release pharmaceutical dosage form containing EPAG, the controlled-release pharmaceutical composition being suitable for local injection into an affected area. The present invention also relates to a controlled-release pharmaceutical composition in powder form for preparing the pharmaceutical composition suitable for local injection, and a kit for preparing the pharmaceutical composition comprising an aqueous injection vehicle and a controlled-release dosage form or a mixture of controlled and immediate-release dosage forms containing EPAG, the pharmaceutical composition optionally including an excipient. The composition is useful for local injection in patients to improve stem cell homing and / or treat non-malignant hematological disorders, malignant hematological diseases, primary immunodeficiencies, autoimmune diseases, inborn errors of metabolism, and / or degenerative diseases / injuries.

The utility model discloses a device for local perfusion of cryogenic liquid through internal carotid artery, and relates to the technical field of artery perfusion of cryogenic liquid, the device comprises a heat preservation box body and a heat preservation box cover, a temperature control mechanism is installed on the heat preservation box cover, an injection pump is installed in the heat preservation box body, an injector is installed on the injection pump, and the injector is connected with the heat preservation box cover. A PE injection tube is inserted into a nipple of the injector, a cold insulation mechanism is arranged on one side of the heat preservation box body, and a plurality of ice bags are placed in the heat preservation box body; the injection is kept in a low-temperature state through the ice bag, the temperature control mechanism and the cold insulation mechanism, local injection is performed through the low-temperature injection, complications possibly caused by whole-body cooling are avoided, and compared with traditional local cold compress, the local low-temperature technology can quickly and evenly reduce the temperature of target brain tissue, and the cold compress efficiency is improved. Therefore, the metabolic activity of brain tissues is more efficiently inhibited, the oxidative stress is relieved, and the cell injury is relieved.

The invention discloses a 5-fluorouracil atropine double-drug sustained release preparation based on temperature-sensitive hydrogel as well as a preparation method and application of the 5-fluorouracil atropine double-drug sustained release preparation. The double-drug sustained release preparation is prepared from the following raw materials: a vagus nerve blocking agent, 5-fluorouracil (5-FU) and temperature-sensitive hydrogel (PLEL), wherein the vagus nerve blocking agent comprises atropine. According to the invention, the chemotherapeutic drug 5-FU and the vagus nerve signal blocking agent (such as atropine) are co-delivered through the temperature-sensitive hydrogel for the first time to realize'double strike 'on gastric cancer tumors, that is, tumor cells are directly killed and cancer-promoting nerve signals are blocked, so that the treatment effect on gastric cancer is remarkably improved. Besides, the double-drug sustained-release preparation is high in safety and good in sustained-release effect, 5-FU and the vagus nerve blocker can be accurately delivered to a tumor area through local injection and in-situ gelation of the temperature-sensitive hydrogel, whole-body exposure of the drug is reduced, local residence time is prolonged, and toxic and side effects are reduced.

The invention discloses a PDGFD derived peptide as well as a preparation method and application thereof. The invention designs and synthesizes a PDGFD derived peptide. A verification result shows that the PDGFD derived peptide can significantly promote the two-way differentiation of dentin formation and vascularization of dental pulp mesenchymal stem cells. The derivative peptide disclosed by the invention has the advantages of small molecule, high stability, strong binding force and easiness in synthesis. The synthesized polypeptide provides a novel peptide medicine for tooth regeneration, can be applied to stem cell culture, tissue engineering scaffolds, local injection preparations and the like, improves the regeneration efficiency, and has wide application prospects in the fields of tooth regeneration, dental pulp repair, osteoporosis and other hard tissue regeneration.

The invention discloses application of NAC in preparation of a medicine for treating temporomandibular joint disorder, and particularly discloses application of the medicine in effectively improving TMD joint tissue oxidation resistance, inhibiting inflammation level, promoting extracellular matrix secretion and inhibiting iron (ferrous) ions and lipid peroxides so as to improve cartilage injury, relieve pain in a condylar process region and improve osteoarthritis. As a clinical common medicine, NAC is low in cost, high in availability, excellent in cell and tissue safety and high in practicability. The medicine can be safely applied to TMD treatment by means of condyle local injection or condyle region skin application (microneedle) and the like, has important significance in clinical medication of TMD, and has good medication value and application prospect.

The invention discloses a composition for promoting skeletal muscle injury regeneration and application thereof, and belongs to the technical field of medicines. In order to solve the technical problems that in the prior art, the skeletal muscle injury regeneration promotion effect of nutrients is insufficient, and the new application of eleutheroside B in the field is undefined, the invention provides a composition for promoting skeletal muscle injury regeneration, and the composition effectively shortens the regeneration time of skeletal muscle after chemical injury or mechanical injury and improves the skeletal muscle regeneration effect. The maturity of new muscle fibers is improved; the composition can be in oral dosage forms such as instant powder, oral liquid or tablets, can take effect on the day of injury, does not need local injection, is convenient to use, and is suitable for preparing functional food or formula food for special medical purposes for shortening the regeneration time of skeletal muscle after injury and improving the maturity of new muscle fibers. And a new technical scheme is provided for nutrition intervention of skeletal muscle injury.

The invention discloses application of a nitric oxide synthase inhibitor in preparation of a tumor treatment medicine, and belongs to the technical field of biological medicines. Experiments prove that the feasibility of injecting the NOS inhibitor NOS1-IN-1 into a tumor to target the NOS / CREB / BNNF pathway so as to inhibit mouse breast cancer innervation is realized. The development of the mouse breast cancer is successfully inhibited by applying NOS1-IN-1 local injection. The application provides favorable support evidence for the development of a strategy for inhibiting tumors by blocking innervation, especially in the aspect of safety, side effects caused by traditional tumor denervation are reduced, a new view angle for inhibiting tumor progression is provided, and the application has important scientific research value and application potential.

The invention discloses an extracellular vesicle for treating facial nerve injury and a preparation method thereof. The hNSCs-EVs are separated from an hNSCs conditioned culture medium through an ultracentrifugation method, the particle size of the hNSCs-EVs is 100-150nm, and the hNSCs-EVs express CD9, CD63 and TSG101 markers. Experiments prove that when hNSC-EVs is locally injected to the injured part of facial nerves, functional recovery of the facial nerves can be remarkably promoted, electrophysiological signals can be improved, and axon regeneration, myelin sheath formation and Schwann cell activation can be effectively promoted. The invention provides a brand new treatment strategy which is safe, effective, easy to store and standard for facial nerve injury, and has a wide clinical application prospect.

The application discloses a kind of customized analgesic hydrogel and its preparation and application.Specifically, the application discloses a new analgesic target, screens suitable drugs, and according to the characteristics of drug molecules, two-step method is customized to obtain sustained-release analgesic hydrogel.The two-step method is specifically divided into the following: first, according to the structure of drug molecules, aldehyde-based hyaluronic acid is synthesized to realize chemical drug loading;Second, adjust the concentration of Schiff base to form a double grid environment to realize injectability.Load the inhibitory drug TAPI-1 for the new target ADAM17 of stomatognathic inflammatory pain, construct a drug delivery system with targeted delivery, sustained-release analgesia, local injection and long-acting effect.Compared with the prior art, the drug delivery system obtained by the application has excellent sustained-release performance, the prolonged drug release is consistent with the hyperalgesia window period of stomatognathic inflammatory pain, precise and effective pain management is achieved, and the operation is simple, and has good conversion application prospect.

A leakage inhibiting agent includes a gelatin hydrolysate having a weight average molecular weight of 5000 or less, wherein a degree of viscosity at 25°C of a first solution obtained by dissolving the gelatin hydrolysate in phosphate buffered saline and adjusting the concentration of the gelatin hydrolysate to 40% by mass is 20 mPa s or less.

The present invention relates to a controlled release pharmaceutical composition comprising at least one controlled release pharmaceutical dosage form comprising EPAG wherein it is suitable for its topical injection at an affected site. The invention also relates to a controlled release pharmaceutical composition in powder form and a kit comprising an aqueous injection vehicle and a controlled release dosage form or a mixture of controlled release and immediate release dosage forms comprising EPAG wherein the pharmaceutical composition optionally comprises an excipient for the preparation of a pharmaceutical composition suitable for topical injection thereof. The compositions may be used for topical injection in a patient, for improving homing of stem cells, and / or for treating non-malignant blood disorders, hematological malignancies, primary immunodeficiencies, autoimmune diseases, innate metabolic deficiencies, and / or degenerative diseases / injuries.

This invention provides an injectable meloxicam, its preparation method, and its uses. The injectable formulation comprises meloxicam, an external aqueous phase, and liposomes. The liposomes contain an internal aqueous phase, which is a salt solution containing metal ions. The meloxicam can form an insoluble salt with the metal ions and be stably loaded in the aqueous phase within the liposomes. This injectable formulation has a high drug loading capacity and good storage stability. After intravenous injection into the bloodstream, it can rapidly release the drug to exert an analgesic effect. It can also be used for local injection in joint cavities to improve local analgesia and anti-inflammatory effects and reduce the dosage required for systemic administration.

Mammals typically heal with fibrotic scars. Treatments to regenerate human skin and hair without a scar remain elusive. Mice lacking C-X-C motif chemokine receptor 2 (CXCR2-KO) displayed robust and complete tissue regeneration across three different injury models, including skin, hair follicle, and cartilage. Remarkably, wild type mice receiving plasma from CXCR2-KO mice through parabiosis or injections healed wounds scarlessly. A comparison of circulating proteins using multiplex ELISA revealed a 24-fold higher plasma level of granulocyte-colony stimulation factor (G-CSF) in CXCR2-KO blood. Local injections of G-CSF into WT mouse wound beds reduced scar formation and increased hair follicle regeneration by 6-fold. G-CSF directly polarized macrophages into an anti-inflammatory phenotype, and both CXCR2-KO and G-CSF-treated mice recruited more anti-inflammatory macrophages into injured areas. These results improve our molecular understanding of scarless tissue regeneration and introduce a new therapeutic approach for cutaneous wounds and hair regeneration. Provided are compositions and methods relating to treating wound healing pathologies.

The utility model relates to the technical field of medical treatment, and discloses an injector which comprises a needle shell, an injection needle, a driving unit and a detection unit. The injection needle is arranged at one end, close to injection skin, of the needle shell and has a first state of being arranged in the needle shell and a second state of extending out of the needle shell; the driving unit is used for driving the needle shell to move in at least two directions; the detection unit is arranged on the needle shell and used for forming a subcutaneous image when the injection needle is in the first state. By arranging the detection unit, the subcutaneous medicine exosmosis range of the patient can be detected in real time, and medical staff with less experience can accurately find the position of injection of the local sealing liquid according to the medicine exosmosis range. When the local sealing liquid is injected, a medical worker adjusts the position of the injection needle through the driving unit, and the injection angle of the injection needle can be adjusted in real time. On the basis, the injection of the local sealing liquid can be operated by medical staff with less experience, so that the technical effect of reducing the pressure of medical resources is achieved.

The invention discloses a medicine for promoting fracture healing and application thereof, relates to the field of biology and medicine, and solves the technical problems that in the prior art, a fracture patient has complications, cannot heal normally and causes heavy burden to the patient, and the existing medicine is weak in effect and large in side effect. The effective component of the medicine for promoting fracture healing is a high-selectivity inhibitor TMG with OGA, the CAS number is 1009816-48-1, the molecular formula is C9H16N2O4S, the molecular weight is 248.299, and the medicine has the performance of increasing the O-GlcNAc glycosylation modification level. The TMG is locally injected at the fracture position to promote fracture healing, including increase of callus formation and promotion of mineralization degree, the process is accompanied by increase of the number of osteoclasts at the same time, an experimental mouse does not show abnormal reaction, the medicine is non-toxic to main organs, and it is indicated that the TMG can be applied to promotion of fracture healing and has a good application prospect. And a new treatment target is provided for fracture healing delay.

The invention belongs to the technical field of biological medicine, and particularly relates to an extrahepatic targeting lipid nanoparticle composition and application thereof. The lipid nanoparticle composition is prepared from the following raw materials: SM1012, DSPC (Distearoyl Pyrrolidone), beta-sitosterol and DMG-PEG (Dimethyl Glycol-Polyethylene Glycol) The DSPC accounts for 20%-30% of the lipid nanoparticle composition in percentage by mole. The lipid nanoparticles can significantly change the in-vivo distribution behavior in different injection modes. Different from the characteristic that a large number of traditional lipid nanoparticles are enriched in the liver after being injected in different modes such as intramuscular injection, the lipid nanoparticles can effectively reduce targeted aggregation towards the liver after being injected in the same way, so that high-concentration retention and enrichment in a local injection area are realized, and the lipid nanoparticles have the advantages of high bioavailability and high bioavailability. The bioavailability of the medicine at a target part can be improved, the whole body exposure and the potential hepatotoxicity are reduced, and a better delivery strategy is provided for local precise administration.

The invention belongs to the technical field of biomedical materials, and particularly relates to a MoS2 and Bi2S3 belonging to HA biological piezoelectric material as well as a preparation method and application of the MoS2 and Bi2S3 belonging to HA biological piezoelectric material. The preparation method comprises the following steps: growing a MoS2 thin layer on the surface of a Bi2S3 nanorod to prepare MoS2 and Bi2S3; the preparation method comprises the following steps: dispersing MoS2 at Bi2S3 into a hyaluronic acid solution to obtain MoS2 at Bi2S3 belonging to HA; the material has the following characteristics: (1) the activity of catalase-like and glutathione-like reductase is obviously enhanced under the ultrasonic action, and active oxygen is efficiently removed; hydrogen and electrical stimulation are generated in the inflammatory microenvironment through the piezoelectric effect, expression of inflammatory factors is inhibited, and cartilage repair is promoted. The preparation process of the material is simplified, the material is suitable for treating inflammatory joint diseases such as arthritis and synovitis, and targeted therapy can be achieved through local injection or articular cavity drug delivery.